Related Experiment Video
Updated: Jun 27, 2026
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema
Rishi P Singh1,2, David C Tabano3, Durga S Borkar4,5
1The Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Background And Objective:
This study assessed real-world treatment patterns and 1-year outcomes among patients with diabetic macular edema (DME) initiating faricimab.
Patients And Methods:
FARETINA-DME is a retrospective study using data from the IRIS® Registry for patients diagnosed with DME initiating faricimab from February 2022 to March 2023.
Results:
Seven hundred eighty-six (786) treatment-naive patients (970 eyes) and 4,862 patients (6,728 eyes) previously treated with anti-VEGF therapy were included. Visual acuity improved by 4.5 ± 15.8 (mean ± SD) letters in treatment-naive eyes (P < 0.001) and was maintained in previously treated eyes at injection-7. Central subfield thickness (CST) improved by -48.7 ± 82.7 μm in treatment-naive and -50.7 ± 101.1 μm in previously treated eyes (both P < 0.0001); 42.3% and 43.8% had achieved/maintained CST ≤ 280 μm at injection-7. Dosing frequency was reduced during the second 6 months (mean 1.9 to 2.7 injections) versus the first 6 months (3.4 to 3.9) of treatment.
Conclusion:
One-year outcomes among patients with DME initiating faricimab in clinical practice support the real-world effectiveness and extended durability of treatment.
More Related Videos
08:10An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
